"What end of Eli Lilly's weight-loss drug shortage means for the competition"
The US Food and Drug Administration confirmed Thursday that Eli Lilly (LLY) has increased production of its blockbuster weight-loss drug Zepbound and type 2 diabetes drug Mounjaro, implying the company can now supply enough doses to meet current demand.
The metrics used to determine the current demand is not specified by the FDA — and the drug shortages website provides an important caveat: "Even when a medication is available, patients may not always be able to immediately fill their prescription at a particular pharmacy," the FDA said on its site addressing the Mounjaro and Zepbound listing.
Like
Comment
Share
